This site is intended for healthcare professionals
Patient and doctor speaking
Hidradenitis suppurativa (HS) Learning Zone
Declaration of sponsorship Novartis Pharma AG


Declaration of sponsorship Novartis Pharma AG
Read time: 220 mins
Last updated:5th Jul 2023
Published:16th Sep 2021

Hidradenitis suppurativa (HS) is a painful and psychologically distressing disease that requires early diagnosis and treatment. Join Dr Joslyn Kirby and explore:

  • Diagnostic techniques and the essential need for earlier diagnosis
  • Pathophysiological mechanisms and the burden of HS in our animation
  • Current and future treatments in video interviews, and summaries of the latest research into emerging and investigational treatments from key congresses in 2022

Meet Olivia in our animated patient case study below and learn about the importance of staying up to date on the latest developments in HS, the impact of this burdensome disease, and the shifting treatment landscape.

What is known about the complex pathophysiology of hidradenitis suppurativa? Discover the latest research uncovering the mechanisms behind this burdensome disease as well as the prevalence, symptoms, need for early diagnosis, and treatments currently available for HS. Also discover how an understanding of pathophysiology has led to the identification of multiple investigational therapeutic targets for hidradenitis suppurativa.

Explore the latest developments as investigational treatments progress through clinical trials, including key results presented at the 2022 EADV congress

This Learning Zone has been developed by EPG Health with expert insights provided by Dr Joslyn Kirby.

Note: Olivia is a theoretical patient case for educational purposes only1.

Meet the expert

Dr Joslyn Kirby

Dr. Kirby is a dermatologist and clinician-researcher at Penn State Hershey. She earned her medical degree from the University of Virginia, then completed her dermatology residency at the University of Pennsylvania. In her clinical and research work, she is interested in acneiform conditions, especially, hidradenitis suppurativa, including its effects on people, outcome measurement, and pathomechanisms. She is the principal investigator of a number of clinical research trials.

Disclosures: Dr Kirby has been on advisory boards for: AbbVie, Incyte, Novartis and UCB, and has been a consultant for: AbbVie, Alumis, DermTech, Guidepoint, Incyte, Insmed, Janssen, Moonlake, Novartis and UCB. Dr Kirby has also been a speaker for: AbbVie, Novartis, UCB and Janssen.